Filing Details

Accession Number:
0001708138-22-000030
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-31 16:04:48
Reporting Period:
2022-03-29
Accepted Time:
2022-03-31 16:04:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc. REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1174475 S Michael Brown 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-29 1,522 $374.12 2,604 No 4 M Direct
Common Stock Disposition 2022-03-29 1,522 $699.00 1,082 No 4 S Direct
Common Stock Acquisiton 2022-03-30 408 $374.12 1,490 No 4 M Direct
Common Stock Disposition 2022-03-30 408 $699.00 1,082 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2022-03-29 1,522 $0.00 1,522 $374.12
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2022-03-30 408 $0.00 408 $374.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,839 2030-01-02 No 4 M Direct
2,431 2030-01-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,000 Indirect by SLAT
Common Stock 7,162 Indirect by Trust
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
  2. These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  3. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.